劲威生物医药科技

Kingwell Biopharma is a clinical-stage biotechnology company headquartered in Shanghai, China, specializing in the development of next-generation small molecule drugs for oncology. The company focuses on targeting traditionally undruggable proteins within the RAS/MAPK signaling pathway and other critical oncogenic drivers using its proprietary protein-protein interaction (PPI) platform. Kingwell's lead programs include inhibitors of SHP2 and SOS1, which are designed to treat various solid tumors both as monotherapies and in combination settings. Founded by industry experts with extensive experience in global pharmaceutical R&D, the company is backed by prominent venture capital firms. The research team leverages structure-based drug design and advanced screening technologies to identify novel chemical entities with high specificity. Kingwell aims to address significant unmet medical needs in patients with KRAS-mutant and other MAPK-driven cancers.